Florence Tantot
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.
Journal: European urology
Published: March 24, 2025
High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 26, 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 07, 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Journal: European urology oncology
Published: May 23, 2023
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 01, 2022
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2022
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Journal: Clinical genitourinary cancer
Published: January 26, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Journal: European urology
Published: January 20, 2021
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.
Journal: Critical reviews in oncology/hematology
Published: June 04, 2020
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Journal: Frontiers in oncology
Published: July 18, 2019
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 14, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026